Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck, Amgen Invest In Medical Video Game Developer Akili

Executive Summary

Akili Interactive Labs Inc., a digital medicine company, has secured an additional $11.9m funding via series B financing with backing from Merck KGaA and Amgen Inc.

You may also be interested in...



BI Finds Right Fit For Digital Therapeutic Partnership With Click

Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m. 

Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development

Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.

Fundraising Cognitive Disorder Videogame Maker Akili Has Big Pharma Buy-In

What if a video game could treat a player's cognitive disorder? It may sound like a sci-fi fantasy, but a company developing such a platform has secured the backing of Shire and Jazz Venture Partners, entered into a partnership with Pfizer and has recently raised $30.5m in equity investments.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel